Harm reduction is the position that drug policy should be evaluated primarily by whether it reduces the measurable harms of drug use - to individuals, families, and communities - rather than by whether it expresses moral disapproval of drugs or achieves abstinence. Holders of this view argue that prohibition and criminalization consistently fail on their own terms, and that pragmatic interventions such as needle exchanges, supervised consumption sites, naloxone distribution, drug checking services, and decriminalization reduce death, disease, and social damage without requiring users to stop using. The viewpoint is held by public health researchers, harm reduction practitioners, civil libertarians, addiction medicine specialists, and a significant portion of the drug policy reform movement.

Harm reduction advocates argue that drug prohibition has never achieved its stated goal of eliminating or substantially reducing drug use. They point to a century of evidence - beginning with alcohol prohibition in the United States (1920-1933) - showing that demand for psychoactive substances is relatively inelastic, and that prohibition drives markets underground without meaningfully suppressing consumption. In underground markets, users cannot know the purity or dosage of what they are consuming, dramatically increasing overdose risk. The fentanyl contamination of the illicit drug supply, which harm reduction advocates regard as a foreseeable consequence of prohibition, is cited as a current example: users seeking heroin, methamphetamine, or counterfeit pills now routinely encounter a substance many times more potent and lethal than what they sought.¹⁾

Proponents of harm reduction contend that the harms associated with drug use are substantially amplified by criminalization. Arrest, prosecution, and incarceration disrupt housing, employment, and family relationships - factors that strongly predict addiction severity and recovery outcomes. Fear of legal consequences deters users from calling emergency services during overdoses (the so-called “Good Samaritan problem”), seeking medical care, or disclosing drug use to clinicians. Criminalization also concentrates enforcement burden on low-income and minority communities, producing harms that extend far beyond the individual user. Harm reduction advocates argue that these downstream effects are policy choices, not inherent features of drug use itself.²⁾

The harm reduction viewpoint holds that several specific interventions have strong empirical support for reducing death and disease:

• Needle and syringe programs (NSPs) reduce transmission of HIV and hepatitis C among people who inject drugs without increasing overall drug use, a finding harm reduction advocates regard as well-established across dozens of countries and decades.³⁾
• Naloxone distribution to users, families, and bystanders allows reversal of opioid overdoses before emergency services arrive. Advocates argue that restricting naloxone access on the grounds that it “enables” drug use produces measurable, preventable deaths.
• Supervised consumption sites (SCS) - facilities where users can consume pre-obtained drugs under medical supervision - have operated in Canada, Switzerland, the Netherlands, and elsewhere. No overdose death has been recorded inside an SCS. Advocates point to Insite in Vancouver, British Columbia, which has been studied extensively and associated with reduced overdose mortality in its surrounding neighborhood.⁴⁾
• Drug checking services, which allow users to test substances for adulterants and potency before consumption, are advocated as a direct response to the contaminated illicit supply.
• Medication-assisted treatment (MAT) with methadone or buprenorphine is regarded by harm reduction advocates as a gold-standard intervention that reduces illicit opioid use, overdose mortality, and criminal activity, and should be available on demand without bureaucratic barriers.

Many harm reduction advocates ground their position in a principle of individual autonomy: competent adults have the right to make decisions about their own bodies, including decisions that carry risk. On this view, the proper role of policy is to reduce the external costs of those decisions - to third parties, to public health infrastructure - not to punish people for making choices the state disapproves of. This positions harm reduction within a broader classical liberal and libertarian tradition that is skeptical of paternalism.⁵⁾

A related principle - non-judgment toward people who use drugs - is operationally significant: harm reduction practitioners argue that services delivered without moral condemnation are more likely to be used, and that sustained engagement with services is itself a pathway toward reduced use or abstinence for users who choose that goal.

Harm reduction explicitly rejects the view that abstinence must be the goal of every intervention, or that providing services to active users “sends the wrong message.” Advocates argue that this objection has the moral logic backwards: refusing to provide a clean needle or a dose of naloxone to someone who is going to use drugs regardless does not prevent drug use - it only increases the probability that the use will be fatal or disease-transmitting. The marginal deterrent effect of withholding services is, on this view, negligible or nonexistent, while the marginal harm of withholding them is concrete and measurable.

The harm reduction movement emerged in practice before it was named as such. In the 1920s and 1930s, British clinicians under the so-called British System dispensed heroin and cocaine to registered addicts as a medical matter, treating addiction as a health condition rather than a criminal one. The modern harm reduction movement is often dated to Rotterdam and Amsterdam in the early 1980s, when Dutch drug user organizations and public health authorities, faced with rising HIV transmission among injection drug users, established the first formal needle exchange programs.⁶⁾

In the United States, needle exchanges operated illegally for years before gaining formal recognition. Dave Purchase, a former social worker, founded the first US needle exchange in Tacoma, Washington, in 1988, operating out of a card table on a street corner.⁷⁾ The AIDS crisis accelerated the political case for harm reduction in the United States, as the connection between injection drug use and HIV transmission made the costs of criminalization visible in epidemiological terms.

The opioid crisis beginning in the 2000s, and particularly the rise of illicit fentanyl after approximately 2013, significantly expanded the political coalition around harm reduction. The scale of overdose mortality - more than 100,000 Americans per year by the early 2020s - made the abstinence-only framework difficult to sustain on purely pragmatic grounds, leading to broader adoption of naloxone distribution, Good Samaritan laws, and, in some jurisdictions, drug checking services.

Portugal's 2001 decriminalization of personal possession of all drugs is frequently cited by harm reduction advocates as a natural experiment demonstrating that removing criminal penalties does not increase drug use, while freeing resources for treatment and reducing HIV transmission and drug-related incarceration.⁸⁾

Ethan Nadelmann (b. 1957) - Founder of the Drug Policy Alliance and one of the most prominent American advocates for harm reduction and drug policy reform. Nadelmann combined public health arguments with civil libertarian principles, bringing harm reduction into mainstream policy debate.

Dave Purchase (1941-2008) - Founded the first US needle exchange in Tacoma, Washington, in 1988. Regarded as a foundational practitioner of harm reduction in the American context.

G. Alan Marlatt (1941-2011) - Psychologist at the University of Washington whose research on relapse prevention and harm reduction provided academic grounding for the movement, and who edited the foundational text Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors.

Evan Wood - Canadian addiction medicine physician and researcher at the University of British Columbia whose studies of Insite, Vancouver's supervised injection facility, provided the primary evidence base for supervised consumption as a harm reduction intervention.

Milton Friedman - The Nobel laureate economist is notable for having argued from free-market and anti-prohibition premises to harm reduction conclusions, lending the position intellectual credibility outside its public health home.⁹⁾

Ruth Dreifuss - Former President of Switzerland and member of the Global Commission on Drug Policy, whose advocacy reflects the European tradition of harm reduction as mainstream public health practice.

Harm reduction is not a monolithic position, and serious disagreements exist among its proponents.

Some harm reduction advocates stop at decriminalization of personal possession, arguing that legal regulated markets go beyond what the evidence requires and introduce new risks (commercialization, marketing, increased availability). Others - particularly those influenced by libertarian or classical liberal arguments - contend that only full legalization and regulation eliminates the harms of black markets, and that decriminalization without legalization leaves supply in criminal hands.

A minority within harm reduction holds that the movement should explicitly welcome abstinence as an outcome and partner more closely with recovery communities. Critics within the movement argue that this risks subordinating harm reduction's non-judgmental ethos to abstinence-based frameworks that have historically been used to withhold services from active users.

There is ongoing debate about whether harm reduction should address only physical and medical harms (overdose, disease transmission) or extend to social and structural harms (housing instability, criminal records, poverty). Broader definitions expand the policy agenda but may dilute focus and complicate coalition-building.

The expansion of harm reduction into drug checking services and, in some Canadian jurisdictions, prescribed pharmaceutical-grade drugs for people at high overdose risk (“safe supply”) is contested within the movement. Critics, including some harm reduction practitioners, argue that safe supply programs lack sufficient evidence, may expand drug use, or are logistically unscalable. Proponents argue that the contaminated illicit supply makes these interventions necessary extensions of harm reduction principles.

• Drug Policy - Main Topic
• drug-policy-prohibition-viewpoint - Prohibition Viewpoint
• Drug Policy - Legalization Viewpoint - Legalization Viewpoint
• drug-policy-abstinence-based-viewpoint - Abstinence-Based Treatment Viewpoint
• Drug Policy - History - History
• drug-policy-harm-reduction-viewpoint-debate - Harm Reduction Debate
• Drug Policy - Prohibition Analogy Viewpoint - Prohibition/Drug Policy Analogy Viewpoint
• drug-policy-decriminalization-debate - Decriminalization Debate
• supervised-consumption-sites-controversy - Supervised Consumption Sites Controversy
• portugal-decriminalization-history - Portugal Decriminalization History

<footnote> 1. Friedman, Milton. “The War We Are Losing.” In Searching for Alternatives: Drug-Control Policy in the United States, edited by Melvyn B. Krauss and Edward P. Lazear, 53-67. Stanford: Hoover Institution Press, 1991.

2. Drucker, Ernest. A Plague of Prisons: The Epidemiology of Mass Incarceration in America. New York: The New Press, 2011.

3. Des Jarlais, Don C. “Harm Reduction in the USA: The Research Perspective and an Archive to David Purchase.” Harm Reduction Journal 14, no. 51 (2017). https://doi.org/10.1186/s12954-017-0178-6.

4. Kerr, Thomas, Mark Tyndall, Kathy Li, Julio Montaner, and Evan Wood. “Safer Injection Facility Use and Syringe Sharing in Injection Drug Users.” The Lancet 366, no. 9482 (2005): 316-18.

5. Nadelmann, Ethan. “Thinking Seriously About Alternatives to Drug Prohibition.” Daedalus 121, no. 3 (1992): 85-132.

6. Marlatt, G. Alan, ed. Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors. New York: Guilford Press, 1998.

7. Hagan, Holly, Don C. Des Jarlais, and David Purchase. “The Tacoma Syringe Exchange.” Journal of Addictive Diseases 12, no. 4 (1993): 5-12.

8. Hughes, Caitlin Elizabeth, and Alex Stevens. “What Can We Learn from the Portuguese Decriminalization of Illicit Drugs?” British Journal of Criminology 50, no. 6 (2010): 999-1022.

9. Friedman, Milton, and Thomas S. Szasz. On Liberty and Drugs. Washington, DC: Drug Policy Foundation Press, 1992. </footnote>